Medtronic

Phase A — Understand the business

Lens 1 · Company Overview

Medtronic is the world's largest pure-play medical-device company — "the leading global healthcare technology company," founded 1949, domiciled in Galway, Ireland (a legacy of the 2015 Covidien inversion), audited by PwC since 1963. FY2026 net sales $36,364M, up 8% reported / ~5.8% organic.

After the March 2026 MiniMed (Diabetes) IPO, the company manages three reportable segments:

Reportable-segment sales were $33,079M; total $36,364M includes Diabetes + small items. Customers: hospitals, health systems, physicians, ASCs across 150+ countries; no single customer is >10% of sales. Geography: FY26 U.S. $18,103M / International $18,261M — ~50/50; China ≈ 6% of total revenue. Contract structure is procedural/consumable-and-implant sales (not take-or-pay), increasingly exposed to GPO/IDN centralized purchasing, national tenders, and China volume-based procurement (VBP) pricing pressure.

Lens 2 · Supply Chain

Upstream → MDT → end customer, named where the filing discloses:

• Upstream inputs: components and raw materials "from numerous suppliers in various countries"; certain components/raw materials available only from a sole supplier. Named geopolitical input dependencies: palladium and neon (Russia-supply-dependent, flagged for the Russia/Ukraine conflict). Critical materials "sourced from, processed in, or subject to regulatory oversight in a limited number of jurisdictions."
• Manufacturing: global owned plants; Puerto Rico is a key manufacturing site and the subject of a long-running IRS transfer-pricing dispute (see Lens 10). FDA quality-system requirements make replacing a sole-source supplier slow — a structural rigidity.
• Tariff exposure: imported-goods tariffs/duties added $185M to FY26 cost of products sold; cross-border flows (US↔China, plus Mexico/Canada/EU) are the chokepoint. Note: on Feb 20, 2026 the U.S. Supreme Court ruled the IEEPA tariff regime unconstitutional, and FY27 guidance was later raised on a lower projected tariff hit.
• Downstream: distributors, GPOs/IDNs, national health systems, hospitals, ASCs; a "significant amount" of trade receivables are with national healthcare systems, so country fiscal stability is a collection risk.
• Chokepoints: sole-source components under FDA lock-in; Puerto Rico tax/manufacturing concentration; Strait-of-Hormuz / Middle-East maritime disruption flagged as a supply/energy-cost risk.

Lens 3 · Competitive Advantages (moats)

Real but uneven by franchise:

• Scale & breadth — $36B of revenue, 150+ countries, the broadest device bag in the industry; lets MDT cross-sell enterprise contracts and absorb tariff/FX shocks that would sink a focused rival.
• Switching costs & installed base — implantable rhythm devices (Micra, ICDs), DBS (Percept), spinal-nav ecosystems (AiBLE/StealthStation/Mazor), and InterStim create high physician-workflow and patient lock-in; remote-monitoring (BlueSync) deepens it.
• Regulatory/IP moat — PMA-class approvals, a deep patent estate, and FDA quality-system barriers raise the cost of entry; clinical-evidence requirements protect incumbents.
• Brand & clinical trust — "major shifts in industry market share … occur in connection with product corrective actions, safety alerts, [and] clinical-trial superiority claims" — i.e. the moat is evidence and reliability, and it cuts both ways.
• Bargaining power — eroding on the buy-side it serves: healthcare consolidation, GPO/IDN centralized purchasing, ASC site-of-care shift, and China VBP all compress price. MDT explicitly cites "increased level of price sensitivity". The bear read (Elliott's): the conglomerate's breadth has historically diluted focus and let nimble single-franchise rivals (Boston Scientific in EP/structural heart, Intuitive in robotics, Inspire in sleep) out-innovate and out-grow it.

Lens 4 · Segments

FY26 reportable-segment detail, all ``:

Trend & cause. Cardiovascular is the accelerant and the whole growth story: CRHF +17% on the pulsed-field-ablation ramp (Cardiac Ablation Solutions +80% WW / +137% U.S. ) plus Micra leadless and Aurora EV-ICD. Neuroscience is the laggard (+4%) — Specialty Therapies only +2%, spine/cranial a mature +5%; Neuromodulation +7% is the bright spot (Inceptiv closed-loop SCS, Percept DBS). Medical Surgical +5% is steady, with Acute Care recovering (+7%) and Hugo robotics pre-inflection. Geographic: International (+12% reported, incl. Diabetes +19% ex-US) outran the U.S. (+5%), partly FX-aided. The structural read: one segment (CV) is carrying a portfolio whose other two-thirds grows GDP+ — exactly the concentration Elliott is pressing on.

---

Phase B — Measure performance

Lens 5 · Earnings Result

Two prints anchor this: the FY2026 full year (10-K on the shelf) and the FY26 Q4 release (June 3, 2026, web).

Full-year FY2026 (GAAP):

• Net sales $36,364M (+8% rep / +5.8% organic) — management's framing: "highest annual revenue growth in 10 years"
• Gross profit $23,643M → gross margin 65.0%
• Operating profit $6,467M, operating margin 17.8%, up from $5,955M / 17.8% FY25
• Net income attributable to MDT $4,801M; GAAP diluted EPS $3.73 (FY25 $3.61, FY24 $2.76)
• Non-GAAP pre-tax income $8,656M (FY25 $8,533M); non-GAAP tax rate 17.3%
• R&D $2,873M (7.9% of sales); SG&A $11,784M (32.4%)

Q4 FY2026:

• Revenue $9,807M, +9.9% reported / +6.6% organic — beat
• GAAP diluted EPS $0.96; non-GAAP diluted EPS $1.55 — slight beat
• GAAP operating margin 19.1% (+300 bps); non-GAAP operating margin 25.5% (−230 bps), pressured by a 160 bps MiniMed/Blackstone payment and 80 bps tariffs
• MiniMed IPO timing diluted Q4 EPS ~$0.04

Margins & why. COGS as a % of sales rose YoY, driven by $185M of tariffs/duties + $84M asset write-offs, partly offset by favorable FX. Effective tax rate jumped to 21.2% (FY26) from 16.6% (FY25) — mostly the OECD Pillar Two 15% global minimum tax (Ireland-enacted) plus jurisdictional mix. The One Big Beautiful Bill Act (R&D immediate expensing, enacted July 2025) was not material to FY26 and isn't expected to move FY27+.

Balance-sheet flags: cash & equivalents $1,949M + investments $7,271M; total debt $27,961M (current $1,788M + LT $26,173M) → net debt ≈ $18.7B. Goodwill $42,587M + intangibles $10,146M = $52.7B, or 57% of $93.0B total assets — the Covidien legacy; tangible book is thin. Inventory $5,951M (+8.7% YoY) and receivables $6,643M roughly tracked the +8% sales — no obvious channel-stuffing tell. Reserves for uncertain tax positions $2,951M (Puerto Rico the bulk).

Market reaction: the stock is down ~8% over 52 weeks and −8.3% over 3 months vs. S&P +2.7% — a "beat-and-raise into a falling stock," i.e. the market is pricing skepticism on durability, not the print.

Lens 6 · Earnings Calls (sentiment trend)

No transcripts on the shelf (transcripts=0); sentiment is ``. Tone has shifted from defensive to cautiously assertive across FY26 calls. Management's recurring themes: "disciplined execution," "operational rigor," "highest growth in 10 years," PFA momentum, Hugo milestones, and the Diabetes separation as portfolio "simplification". What changed vs. a year ago: the company now leads with an acceleration narrative and explicit FY27 guidance (organic +6.75–7.25%, EPS $5.90–$6.00) rather than apologizing for ~4–5% growth. What's conspicuously added to the script: Elliott-aligned language on cost discipline and tuck-in M&A. What they've stopped emphasizing: the Diabetes turnaround (now spun off). The skeptic's flag (Needham): the "acceleration" rests heavily on PFA comps that will lap.

Lens 7 · Comps

Large-cap medtech peer table. Multiples `` (stockanalysis.com / Yahoo, June 2026); MDT EV/Sales/P/E corroborated against the live quote. ROE not uniformly sourced → n/a.

Read: MDT is the cheapest large-cap medtech by a wide margin — ~12x EV/EBITDA and ~13x forward earnings versus 18–20x EV/EBITDA and 18–22x forward for BSX/SYK/ABT. The discount is earned (a decade of sub-peer growth) but it is also the entire bull case: if organic growth holds 6–7%, MDT screens as a re-rating candidate; the dividend yield (3.6% vs. ~0–2% for peers) pays you to wait. Live MDT statistics: price $79.34, EV $121.4B.

Lens 8 · Stock-Price Catalysts (what moves MDT)

Pattern over recent years ``:

• Organic-growth surprises & guidance are the dominant driver — the stock trades on the durability of organic growth, not the headline beat (Needham: Hold "until … meaningful and sustainable acceleration beyond 5%").
• Elliott activism (≈Oct 2024) — disclosure of a multi-billion stake, board expansion, cost/M&A mandate; a structural re-rating catalyst and the reason "portfolio" is now a lever.
• PFA franchise — PulseSelect (US approval) and Affera Sphere-9 (FDA Oct 2024) / Sphere-360 (CE Jan 2026) data and ramp; the single biggest growth swing factor.
• Hugo robot — US FDA clearance for urologic procedures (2026); first US soft-tissue surgical robot from a large medtech since Intuitive — a multi-year optionality catalyst.
• Renal denervation (Symplicity Spyral) — CMS National Coverage Determination finalized Oct 2025; reimbursement is the unlock.
• Tariffs / SCOTUS IEEPA ruling (Feb 2026) and FX — macro swing factors; FY27 outlook raised on a smaller tariff hit.
• MiniMed (Diabetes) separation — the March 2026 IPO and full spin path; portfolio-simplification re-rating story.
• Dividend — 49th consecutive annual increase (to $2.88 annualized); the floor under the stock for income holders.

---

Phase C — Judge people & books

Lens 9 · Management

• CEO Geoff Martha — appointed April 2020 (~6 years' tenure); a Covidien-legacy executive who ran the Restorative Therapies/spine group before the top job.
• Track record — mixed-to-improving. The hard fact bulls can't wave away: under Martha the stock is +~15% over a decade and −8% over five years while BSX and Intuitive compounded — sustained sub-peer TSR. The counter: FY26 delivered the best organic growth in 10 years, PFA leadership was built/acquired (Affera) on his watch, and he executed the Diabetes separation and Elliott settlement.
• Skin in the game — light. Martha owns 0.01% of shares ($10.6M); FY comp ~$21.2M, ~94% incentive/equity. Recent insider activity: option exercise + partial sale (Aug) — routine, not a red flag, but insider ownership is low for a founder-quality moat (this is a professional-manager, not a founder, company).
• Capital allocation. FY26 returned $4.2B to shareholders ($3.64B dividends + $1.0B buyback) on $5.4B FCF and $7.3B operating cash. Buyback was cut hard YoY ($1.0B FY26 vs. $3.2B FY25 ) as cash went to debt paydown ($2.93B LT debt repaid) and tuck-ins. M&A is now disciplined tuck-in under an Elliott-influenced "Growth Committee": CathWorks (~April 2026, coronary FFR) and SPR Therapeutics (~$650M, May 2026, peripheral nerve stim). The decade-long critique: Covidien (2015, ~$50B) created the goodwill mountain and arguably bought scale at the expense of growth — the original sin behind today's discount.
• Archetype: professional-manager-led conglomerate, now operating under activist supervision. Implication: the upside is self-help (margin, focus, portfolio surgery) more than visionary bets.

Lens 10 · Forensic Red Flags

Accounting quality is clean for a company this size — PwC issued an unqualified opinion on financials and internal controls; auditor since 1963. Areas to watch:

• Goodwill + intangibles = $52.7B (57% of assets) — the Covidien legacy. No FY26 goodwill impairment, but any sustained growth disappointment in a reporting unit is impairment risk. Tangible equity is thin against $50.1B total equity.
• Non-GAAP vs. GAAP gap — non-GAAP pre-tax income $8,656M vs. GAAP $6,136M; the ~$2.5B bridge is mostly amortization of intangibles ($1,772M) + restructuring + litigation. This is structurally honest for an acquisitive medtech (real amortization of bought technology), but it does mean GAAP EPS ($3.73) is ~40% below the non-GAAP figure the Street capitalizes — know which you're paying for.
• SBC modest — $457M (1.3% of sales); not flattering non-GAAP materially.
• Cash vs. earnings — operating cash $7,330M > net income $4,837M (D&A $2,958M the main bridge); FCF $5.4B comfortably covers the $3.64B dividend (~67% FCF payout) — healthy.
• Critical Audit Matter — Puerto Rico IRS transfer-pricing dispute; total uncertain-tax-position reserves $2,951M, "significant portion" Puerto Rico, tied to a U.S. Tax Court case. A real but bounded, long-disclosed tail risk.
• Italian payback accrual — a +$39M FY26 / −$90M FY25 swing in net sales from Italian medical-device "payback" rulings; a reminder that ex-US government clawbacks distort the top line.

Regulatory findings (read regulatory/regulatory-findings.md):

• SEC: No Litigation Releases and no AAERs naming Medtronic in the 2021-06-21→2026-06-21 window, per EDGAR EFTS (LR + AAER).
• 10-K Item 3 / Note 18 (Legal Proceedings): routine for a device major — IP, product-liability, antitrust, and commercial disputes. Accrued litigation only ~$0.2B (down from ~$0.4B FY25); certain-litigation charges $113M FY26 (vs. $317M FY25). The notable matter — Colibri Heart Valve patent suit (~$106M jury verdict against MDT's Evolut TAVR, Feb 2023) — was reversed in Medtronic's favor by the Federal Circuit (July 18, 2025). DOJ/FTC/state-AG promotional oversight is disclosed as ordinary-course, with no material new enforcement surfaced.
• Non-SEC web check ("Medtronic" (FTC OR DOJ OR FDA OR settlement OR fine OR penalty) enforcement): no material new federal enforcement action surfaced for FY26; device companies carry a chronic tail of FCA/quality matters but nothing rises to thesis-altering in the period.
• Net: No material regulatory or accounting findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K Item 3 / Note 18 as of 2026-06-21. The genuine accounting judgment risks are goodwill and the Puerto Rico tax reserve, both well-disclosed.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection (non-GAAP diluted EPS)

Built bottom-up from FY26 actuals + management's FY27 guide. Base year FY26 non-GAAP EPS ≈ $5.49.

Management FY27 guide: organic revenue +6.75–7.25%, non-GAAP EPS $5.90–$6.00.

Drivers: PFA ramp (lapping tough comps but still net-additive), Hugo US launch optionality, renal-denervation reimbursement, Symplicity/Affera international rollout; offset by ~5% mature-Neuroscience drag, China VBP, residual tariffs (smaller post-SCOTUS), Pillar-Two tax (~17% non-GAAP rate), and ~1% net buyback. Share count ~1,288M diluted, shrinking modestly.

At $79.34, base-case forward multiples: ~13.3x FY27 → ~12.2x FY28 → ~11.2x FY29. That is a deep-value multiple for a 5–9% EPS grower with a 3.6% yield — the math only works as a re-rating call (multiple expands toward the 15–16x medtech-laggard norm) plus dividend, not as an earnings-hypergrowth call.

Brier forecast (would log, but skipped per --watchlist rules — no forecast.ts create in the sweep): "MDT FY27 (ending ~Apr 2027) non-GAAP diluted EPS ≥ $5.95, p≈0.60, resolves 2027-04-30, tags medtronic, deep-dive." Guidance midpoint with a slight haircut for execution/FX/tariff variance.

Lens 12 · Bull vs Bear

Bull case. MDT is a $36B franchise trading at ~13x forward — half the multiple of BSX/SYK — at the exact moment its growth algorithm inflected to a 10-year high (5.8% organic). Three compounding levers: (1) PFA — Cardiac Ablation +80%/+137% US, taking share in the largest EP opportunity in a decade; (2) Hugo — the only large-medtech soft-tissue robot cleared in the US since Intuitive, a multi-year razor/razorblade optionality the market assigns ~$0 to; (3) Elliott-forced self-help — cost-out, Diabetes spin, disciplined tuck-ins (CathWorks, SPR) that lift margin and sharpen the portfolio. Pay a 3.6% dividend (49 straight years of hikes) to wait for the re-rate. The contrarian view the market refuses to see: the conglomerate discount is finally being actively dismantled by an activist, and a 13x multiple already prices permanent mediocrity that FY26 disproved.

Bear case (2–3 permanent-impairment risks). (1) Structural sub-5% organic growth — a decade of TSR underperformance says the breadth is the problem; PFA comps lap, Neuroscience is a +2–4% anchor, and "acceleration" reverts (Needham's explicit Hold thesis). (2) GLP-1 demand destruction — MDT names GLP-1 makers as competitors; obesity drugs threaten long-run demand for cardiac, bariatric-adjacent, and metabolic-disease device volumes. (3) Goodwill/returns — $52.7B goodwill on a business earning ROIC the activist deems sub-par; any reporting-unit stall risks impairment and the "value trap" verdict persists. Pre-mortem (18 months out, thesis broke): PFA growth normalized faster than hoped, Hugo's US ramp was slow against entrenched da Vinci, China VBP + tariffs squeezed margin, organic settled at ~4.5%, and the stock de-rated further to 11x as the market concluded the Elliott catalyst was already spent — the classic value trap. Are multiples too high? No — they're low; the risk is they're justifiably low.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case: The whole long thesis is one number — does organic growth hold above 5%? — and 10 years of evidence says no. Revenue concentration of growth: strip out the PFA franchise and MDT is a ~3–4% grower; PFA's +137% US is a comp that mechanically decays, and Boston Scientific (Farapulse) is the more dangerous PFA competitor bulls underrate — MDT could be the share donor, not taker, as the category matures. Moat is weaker than it looks: in robotics, MDT is a decade behind Intuitive with an unproven Hugo; in EP and structural heart, BSX out-innovates; in sleep/neuro, focused players move faster — the "breadth" moat is really a focus deficit. Capital-allocation history: the $50B Covidien deal is the original value-destroyer — it built the $52.7B goodwill block and a tax structure now exposed to Pillar Two, and a decade later the market still discounts it. Assumptions that must hold for $79: ~6%+ organic sustained, ~17% non-GAAP tax (Pillar-Two risk to the upside), tariffs staying small (post-SCOTUS, but policy is volatile), and FX neutral. If growth disappoints 20–30% (organic to ~4%, EPS growth to low-single-digits): the re-rating thesis dies, the multiple holds ~11–12x, and you own a bond-proxy yielding 3.6% with no capital upside — dead money. Single permanent-impairment scenario: GLP-1s + a focused-competitor share-shift in PFA simultaneously cap CV growth (the only engine) → the conglomerate is revealed as ex-growth → multiple compresses toward 10x and the dividend-growth streak becomes the only reason to hold. Plausibility: moderate, not remote.

Lens 14 · Management Questions (ordered by information value)

1. Strip out PFA: what is the organic growth rate of the rest of the company, and what gets it sustainably above 5%?
2. As PFA comps lap in FY27–28, what specific franchises replace that growth — and what is your honest read on Boston Scientific's Farapulse competitive trajectory?
3. What is the realistic 3-year US revenue and margin path for Hugo against entrenched da Vinci, and at what installed base does it turn accretive?
4. Where does consolidated operating margin go over three years under the Elliott-influenced cost program, and how much is structural vs. one-time?
5. What is the end-state portfolio? Beyond Diabetes/MiniMed, which businesses are candidates for divestiture or further separation?
6. Quantify GLP-1 exposure across the device bag — which franchises see demand destruction vs. creation, and on what time horizon?
7. With buyback cut to $1.0B, what is the capital-allocation priority stack — debt, dividend, buyback, M&A — and what ROIC hurdle governs tuck-ins like CathWorks/SPR?
8. What is the resolution path and worst-case cash exposure on the Puerto Rico IRS transfer-pricing matter ($2.95B reserve)?
9. How exposed is FY27 to residual tariffs after the SCOTUS IEEPA ruling, and what is the China VBP revenue-at-risk?
10. What is the steady-state non-GAAP tax rate under Pillar Two, and the risk it drifts above 17%?
11. What retained economics and timeline govern the rest of the MiniMed separation, and what is the dis-synergy?
12. Which Neuroscience businesses are structurally challenged enough to fix-or-exit, given the +2% Specialty Therapies print?
13. What is the realistic commercial timeline and TAM for adaptive DBS (Percept/BrainSense) and closed-loop neuromodulation as a genuine BCI-adjacent growth vector?
14. How do you defend the dividend-growth streak (49 years) if FCF is pressured — what is the FCF payout ceiling you will not cross?
15. What would you flag as the single most underappreciated risk to the FY27 guide?

---